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Abstract 
 Controlling blood glucose level in ICU is one of the main priorities in 
ICU to decrease mortality rates and morbidity rates and to decrease the 
healthcare cost. The main objective of the present study is design and 
implement an intervention protocol in ICU. The method involved a 
suggested intervention protocol which was applied for 25 ICU patients and 
their findings were compared with 25 ICU patients in control group. Study 
findings showed that the intervention protocol was able to reduce mortality 
rates, positive blood cultures, decreased morning glucose level in the 
intervention group compared with control group. As a conclusion, 
controlling blood glucose level in ICU is considered an appropriate approach 
and leads to better outcome of the patients  
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Introduction  
 The present study is methodological in its nature and puts focus in 
designing an intervention to be implemented in the intensive care unit (ICU) 
to control glucose level. 
 
Common clinical interventions 
 Patients in ICU are predisposed to elevated blood glucose levels 
because of common clinical interventions, such as the use of corticosteroids, 
vasopressors, glucose-containing intravenous fluids used for drug or fluid 
administration, enteral or parenteral nutrition, and dialysis (Krinsley et al., 
2005). 
 
Controlling hyperglycemia in ICU patients 
 Although extensive research efforts during the last decade focused on 
strategies to prevent or reverse the potentially lethal multiple organ failure, 
only few of them revealed positive results. One of these strategies is blood 
glucose control with insulin (Berghe., 2004). Another way for controlling 
hyperglycemia is by controlling the exogenous nutritional inputs (Chase et 
al., 2006). 
 
Mechanisms of blood glucose control with insulin therapy in the ICU 
 Several mechanisms are involved and interrelated in explaining the 
clinical benefits of normoglycemic control; including metabolic and non-
metabolic insulin effects, anti-inflammatory effects, prevention of glucose 
toxicity, and other direct insulin actions on several cell and organ systems. 
The relative contribution of those different mechanisms, however, is 
presently unknown (Derde et al., 2009). 
 
Lowering blood glucose levels 
 Critically ill patients suffer from both hepatic and skeletal muscle 
insulin resistance. The increased metabolic insulin signal was observed in 
postmortem skeletal muscle, but not in liver biopsies of insulin-treated 
patients. This suggests that in critically ill patients exogenous insulin does 
not affect hepatic insulin resistance and lowers blood glucose levels mainly 
through stimulation of skeletal muscle glucose uptake (Langouche et al., 
2007). 
 Insulin therapy also attenuated the cortisol (counter regulatory 
hormone) response to critical illness, without involvement of altered cortisol-
binding activity, also suppress indirectly the synthesis and production of 
TNF and IL-2 which play a role in increased gluconeogenesis (Vanhorebeek 
et al., 2006). 
 
European Scientific Journal June 2016 edition vol.12, No.18  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
311 
Blood glucose control with nutritional inputs 
 Tighter glycemic control is possible by controlling the exogenous 
nutritional inputs exacerbating the original problem. Clinical studies that 
intentionally lowered carbohydrate nutrition have significantly reduced 
average blood glucose levels without added insulin. It was found that feeding 
33% to about 66% of the amount recommended by the American College of 
Chest Physicians (ACCP) guidelines minimized the mortality and 
hyperglycaemia, also the enteral nutrition was preferred over the total 
parental nutrition since the later one causes higher plasma glucose levels 
(Chase et al., 2006). 
 
Insulin infusion pumps 
 In a prospective study of 2500 diabetic patients who underwent 
cardiac surgery, the impact of sliding scale insulin compared with continuous 
insulin infusions titrated to maintain BG concentrations at 150–200 mg/dL 
was evaluated. A significant reduction in the incidence of deep sternal 
wound infections (0.8% versus 2%; p =0.01) was observed in the continuous 
infusion group. Subcutaneous sliding scale insulin alone may be inadequate 
to maintain glycemic control in older critically ill injured patients and in 
patients with greater physiologic insult (Gale et al., 2007). 
 
Insulin protocols in the ICU 
 A lack of information about the importance of normoglycemia in 
critically ill patients is widespread in ICUs (Holzinger et al., 2009). 
However, achieving normoglycemia requires designing and implementing 
insulin protocols which include timing and frequency of glucose 
measurements, insulin infusion rates, and target glucose values. This will 
need education and efforts from the medical staff, including frequent glucose 
monitoring and adjustment of insulin dose. 
 
Less stringent glucose level protocols 
 The benefit of glucose and insulin therapy has been studied in 
diabetic patients experiencing an MI. In the Diabetes Insulin–Glucose in 
Acute Myocardial Infarction (DIGAMI) trial, 620 diabetic patients were 
randomized to receive insulin and glucose infusion until the BG level was 
128–199 mg/dL. Subcutaneous injections of insulin were continued for 3 
months. Results at one year showed a statistically significant reduction in 
mortality from 26.1% in the conventional treatment group to 18.6% in the 
insulin group (p= 0.027) (Malmberg et al., 1995). 
 The most pronounced reduction in mortality was in diabetic patients 
with a low cardiac risk profile who had received no previous insulin 
administration (Malmberg et al., 1995). Furnary et al (1999) showed that the 
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use of an insulin infusion to maintain glucose levels between 150 and 200 
mg/dL decreased the risk of sternal wound infection after coronary artery 
bypass graft surgery in diabetic patients by 58%. 
 In a later study Furnary et al (2003) showed that when the target 
blood glucose level was decreased to less than 150 mg/dl in a cohort of 2612 
patients with diabetes who were undergoing coronary artery bypass grafting, 
compared with historical controls, the absolute mortality was reduced (57%). 
In a prospective, observational study, Finney et al (2003) found that a target 
blood glucose level of less than 145 mg/dl (8.0 mmol/L) may be adequate. 
This target was likely associated with less risk of inadvertent hypoglycemia. 
 Krinsley et al (2005) showed that intermediate blood glucose level 
decrease (<140 mg/dL), and a somewhat less strict level, which was chosen 
primarily for safety of patients and designed to avoid inadvertent 
hypoglycemia, was associated with a 29% reduced in-hospital mortality, 
decreased new organ failure, fewer blood transfusions, and shorter ICU stay 
compared with the historical control group, while the rate of hypoglycemia 
did not increase. The lowest hospital mortality (9.6%) occurred in patients 
with mean glucose concentrations between 80 and 99 mg/dL. 
 
Tight glycemic control protocols (TGC) 
 Some institutions use tight glycemic control (TGC) protocols in their 
intensive care units. TGC protocols became standard of care after the initial, 
very promising, studies demonstrating that it improved patient outcomes 
(Mackenzie et al., 2005). Hyperglycemia and glucose variability in intensive 
care unit (ICU) patients had some clinical experts calling for routine 
administration of intensive insulin therapy to normalize glucose levels in 
hyperglycemic patients (Chase et al., 2007). Typical TGC protocols consist 
of placing postoperative and critically ill patients on a continuous 
intravenous insulin infusion, checking their blood glucose concentrations on 
an hourly basis (or other schedule), and giving a bolus of insulin and/or 
changing the infusion rate of insulin based on the glucose concentration, with 
a goal of maintaining glucose between 4.4 and 6.1 mmol/L (80 and 110 
mg/dL) (Lonergan et al., 2006). 
 Most of the clinical benefits of intensive insulin therapy appear to be 
related to prevention of hyperglycemia, which has been demonstrated to 
adversely affect outcome (Berghe et al., 2006). Intensive blood glucose 
control is achievable using a nurse-directed nomogram. This improved 
control was achieved without substantially increasing resource use (Chant et 
al., 2005). 
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A new range of glycemic control protocol 
 A Joint Statement from the American Diabetes Association and 
American Association of Clinical Endocrinologist (2009) announced that this 
study should NOT lead to an abandonment of the concept of good glucose 
management in the hospital setting. The statement also emphasizes that; 
clinicians should strive for a reasonable control (i.e., glucose levels in the 
mid-100s) in such critically ill patients. The optimal target range for blood 
glucose in critically ill patients remains unclear. 
 
Study objectives 
 The main objective of the present study is to design an intervention 
protocol to control glucose level in ICU. 
 
Methodology 
 We designed an intervention protocol to be implemented in ICU.   
 
Outcomes measured 
 The following measuring variables were taken into consideration for 
appropriate implementation of intervention protocol: 
- Length of ICU stay. 
- Mortality in ICU patients, after 28 days, and 60 days from 
randomization. 
- Length of hospital stay. 
- The need for organ support (inotropes, renal replacement therapy and 
positive pressure ventilation). 
- Incidence of blood stream infections. 
- Use of antibiotics for more than 10 days. 
- Incidence and severity of hypoglycemia. 
- Need for blood transfusion. 
- The presence or absence of hyperbilirubinemia. 
- New kidney injury during ei either a level of serum creatinine twice 
that present on admission to the ICU or a peak level of serum creatinine of 
>2.5 mg per deciliter [220 Xmol per liter]). 
-  Hemoglobin A1C that would provide insight in the hyperglycemic 
exposure of ICU patients. 
- Total dose of insulin given in each protocol. 
- Mean blood glucose level mg/dL for the two groups. 
 
Hyperglycemia management 
 Management of hyperglycemia in the intervention group was with an 
insulin infusion pump protocol, to maintain blood glucose level (BGL) 
within range of 120-160 mg/dL, for ICU patients in general; and within 
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range of 160-180 mg/dL, for septic patients. This is in comparison with the 
control group who was managed by conventional insulin regimen to maintain 
blood glucose level less than 200 mg/dL in a target range of 180-200 mg/dL. 
 
Insulin protocol ranges for intervention group: 
 Blood glucose ranges were defined as severely hypoglycemic ( 44 
mg/dL), hypoglycemic (60 mg/dL), low (60–80 mg/dL), acceptable (80–119 
mg/dL) target (120-160 mg/dL), hyperglycemic (161–250 mg/dL), and 
severely hyperglycemic (>250 mg/dL). For septic patients the target range 
was (160-180 mg/dL) and hyperglycemic range was (181–250 mg/dL). 
Insulin protocol for the intervention group was designed by the study 
members; the target range was set higher than the range of TGC protocols to 
decrease the risk of hypoglycemia. Insulin protocol used in the intervention 
group is shown in Table 1. 
Table 1: Insulin protocol used in the intervention group  
Current blood glucose level, mg/dL Action 
<45 Give 20 ml dextrose 50% 
  
45-59 Give 10 ml dextrose 50% 
60-119 No insulin 
120-160 No insulin 
161-199 
Give insulin 2 units /hr 
Give insulin 3 units /hr 200-300 
>300 Give insulin 4 units /hr 
 
 Blood glucose ranges were defined as severely hypoglycemic ( 44 
mg/dL), hypoglycemic (60 mg/dL), low (60–80 mg/dL), acceptable (80–179 
mg/dL) target (180-200mg/dL), hyperglycemic (>200 mg/dlL, and severely 
hyperglycemic (>290 mg/dL). The insulin protocol for the control group was 
designed by the ICU clinicians, and it has been used as the conventional 
treatment for hyperglycemia in the ICU. Insulin protocol used in the control 
group is shown in Table 2.  
Table 2: Insulin protocol used in the control group 
Current blood glucose level, mg/dL Action 
<45 Give 20 ml dextrose 50% 
45-59 Give 10 ml dextrose 50% 
60-159 No insulin 
160-200 No insulin 
201-250 Give insulin 2 units /hr 
251 -300 Give insulin 3 units /hr 
>300 Give insulin 4 units / hr 
Implementation of the intervention protocol 
 Two groups of ICU patients were randomly assigned into two groups 
intervention group (N=25) and control group (N=25). ICU patients were 
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from King Hussein Medical Center, the Royal Medical Services. A 
randomized controlled trial was conducted. 
 
Study findings 
 As shown in table 3, variables associated with intervention protocol 
are described. In intervention group, 96% of patients were treated with 
insulin compared with 72% in control group, this variation in insulin 
treatment was statistically significant (p=0.021). Patients in intervention 
group received more insulin (28.32 IU) compared with those in control group 
(14.62 IU), and the difference of insulin dose was statistically significant 
(p=0.002). The results also showed that  morning blood glucose in 
intervention group (139 mg/dl) was  significantly (p=0.001) less than that in 
control group (174 mg/dl). 
 Corticosteroid treatment was higher in intervention group compared 
with control group, but not statistically significant (0.568). Mortality rates 
were lower in intervention group at day 28, and day 60, but this was not 
statistically significant (p=0.370, p=0.555). Renal replacement therapy was 
8% in intervention group and this was less than that in intervention group 
12%, but this was not statistically significant (p=0.139). Positive blood 
cultures were 8% in intervention group, and 36% in control group, but this 
was not statistically significant (p=0.068).  
Table 3: Variables associated with intervention protocol in ICU 
p value Control group Intervention group Variable  
0.021 72% 96% Treated with insulin (%) 
0.002 14.62± 12.26 28.32± 16.38 Insulin dose, units/day (M+SD) 
0.001 174± 16.69 139± 17.09 Morning blood glucose (M+SD) 
0.568 40% 48% Corticosteroid treatment 
0.555 40% 32% Death, (%) at day 60 
0.37 40% 28% Death, (%) at day 28 
0.139 12% 8% Renal replacement therapy 
0.068 36% 8% positive blood cultures 
 
Discussion  
 Hyperglycemia and glucose variability in intensive care unit (ICU) 
patients made some experts call for routine administration of intensive 
insulin therapy to normalize glucose levels in hyperglycemic patients on the 
assumption that treatment aiming at normoglycemia will benefit patients. 
Others, however, have raised concerns over the optimal glucose level, the 
accuracy of measurements, the resources required to attain tight glycemic 
control (TGC), and the impact of TGC across the heterogeneous ICU 
population. 
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A reasonable goal insulin protocol 
 The apparent contradiction between the adverse effects of 
hyperglycemia and increased administration of insulin provokes debate over 
the most appropriate target for glucose control. Controlling hyperglycemia 
without being too tight will result in the most benefit without increasing the 
risk for severe hypoglycemia (Bochicchio et al., 2008). A Joint Statement 
From the American Diabetes Association and American Association of 
Clinical Endocrinologists (2009) announced that it is important to consider 
that the severely ill patients in NICE-SUGAR trial -that reported an increase 
in mortality rate, and episodes of severe hypoglycemia with tight glycemic 
control- were treated intensively with intravenous insulin to very tight targets 
(target glucose level was 81–108 mg/dL) compared to a control group whose 
glucose control was good (average glucose 144 mg/dL). This study should 
NOT lead to an abandonment of the concept of good glucose management in 
the hospital setting. In light of the recently published NICE-SUGAR data, a 
systematic review and a new meta-analysis provide an updated estimate of 
the effect of such therapy on the risk of hypoglycemia and death. It has 
suggested that TGC protocols offer limited if any benefits in critically ill 
adults and revealed that these protocols resulted in a 3- to 5-fold increased 
risk of hypoglycemia. The meta-analysis examined 29 randomized controlled 
trials that met the predefined inclusion criteria with strict glycemic goals. Of 
the 27 trials that examined mortality as an endpoint, 16 favored TGC and 11 
favored usual care, but the reductions in relative risk were statistically 
significant (95% confidence) in only 2 of the 16 favoring TGC and in none 
of the 11 favoring usual care. The only outcome for which TGC 
demonstrated a significantly reduced risk was the development of 
septicemia. This was seen in surgical intensive care patients but not in 
medical ICU which cannot exclude the possibility that some patients may 
benefit from intensive insulin therapy (Donald et al., 2009). 
 In our study a new range of glucose level was set to control 
hyperglycemia with an insulin infusion pump protocol used in the 
intervention group. A goal was to maintain blood glucose level within range 
of 120-160 mg/dL, for ICU patients in general in the intervention group, and 
the range of 160-180 mg/dL was set for septic patients, to prevent 
hypoglycemia, which is risky in this particular ICU population. While 
conventional treatment with an insulin infusion pump was maintained in the 
control group; that is to maintain blood glucose level less than 200 mg/dL for 
ICU patients in a target range of 180-200 mg/dL. The above ranges for the 
intervention group were higher than the TGC protocol since negative 
outcomes reported in the NICE-SUGAR study increased the need to target 
safer blood glucose level at the same time controlling hyperglycemia and 
preventing bad outcomes; a glucose levels in the mid-100s. Our goal was set 
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before the recommendations by ADA and AACE were declared (Moghissi et 
al., 2009). 
 The management of blood glucose levels was standardized. Nearly all 
patients received their assigned treatment. The mean blood glucose levels 
differed significantly between the two treatment groups during the study 
period (143.70±12.78 versus 175.56±14.07 mg/dL, p<0.001). When insulin 
resistance decreased, lower insulin rates were able to maintain better blood 
glucose levels. In this randomized controlled trial involving adults in the 
mixed ICU we found that a new target of blood glucose control that was used 
in the intervention group, as compared with a conventional glucose control in 
the control group, did not increase the absolute risk of death at 28 days and at 
60 days. 
 The difference in mortality remained not significant after adjustment 
for potential confounders at 28 days (p=0.370), and at 60 days (p=0.555), 
between two groups in our study. This finding agrees with the result of a 
meta-analysis stating that the different targets of intensive insulin therapy 
(glucose level [ 6.1 mmol/L versus [ 8.3 mmol/L) did not influence either 
mortality (Fahey et al., 2009). It was noticed by secondary subgroup analysis 
for the primary outcome that the percentage of death was significantly higher 
in medical ICU patients than surgical ICU patients (p= 0.015), indicating that 
surgical patients may benefit more from insulin treatment. As found in 
previous studies (Berghe et al., 2001, He et al., 2007) and a meta-analysis 
(Donald et al., 2009).  
 In our study the rate of positive blood cultures was lower in the 
intervention group than that in the control group; (8% and 32% respectively) 
(p=0.068), which reflects reduction in the risk of septicemia. This finding 
was reported previously by other studies (Berghe, et al., 2001; Grey, et al., 
2004; Cromphaut, et al., 2007). 
 
Conclusion  
 Designing and implementation of intervention protocol in ICU led to 
positive impacts in reducing mortality rate, morning glucose level, positive 
blood cultures, and renal replacement therapy among intervention group 
compared with control group. 
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